Reducing Acute Upper Gastrointestinal Side-Effects of Thoracic Irradiation

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE2

Enrollment: 142

Sponsor: Memorial Sloan Kettering Cancer Center

Location: Memorial Sloan Kettering Cancer Center Basking Ridge (All Protocol Activities) Basking Ridge New Jersey

Summary

The purpose of the study is to explore options for preventing and reducing symptoms of radiation esophagitis (RE). The researchers will also look what symptoms participants experience, and whether there are differences in weight loss in participants.

Eligibility Criteria

Inclusion Criteria: * Patients being treated with thoracic irradiation with high-risk esophageal dose as determined below: Esophageal dose: * V50 ≥ 15% (25-35 once daily fractions) or 40 twice-daily \[BID\] fractions) * V40 ≥ 15% (15-24 once daily fractions or 30 twice-daily \[BID\] fractions) * V30 ≥ 15% (10-14 once daily fractions) * Age 18 years of age or older. Exclusion Criteria: * Known inability to take Sucralfate (tablet and/or suspension form), per physician discretion * PEG tube * Actively taking any opioid pain medications prior to radiation therapy * History of an opioid use disorder

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05659576). StuddyBuddy aggregates publicly available trial information.